Loading...
Loading...
Shares of
Mylan NVMYL were trading higher by 0.85 percent early Tuesday morning after the company
announced the launch of Linezolid Tablets, 600 mg.
Linezolid is a generic version of
Pfizer Inc.PFE's Zyvox Tablets and is intended for adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria.
Mylan noted that it has already received final approval from the US Food and Drug Administration. The company added that Linezolid Tablets had US sales of approximately $457.8 million for the 12 months ending September 30, 2015, according to IMS Health.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in